Potential antileukemic effect of gamma delta T cells in acute lymphoblastic leukemia.
The immune response to leukemia is poorly understood. We postulated that nonmalignant T lymphocytes remaining within bone marrow from children with newly diagnosed ALL could be involved in this immune response. T lymphocytes which expressed gamma delta TCR comprised less than 1% of ALL marrow cells. A preferential outgrowth of gamma delta T cells within the CD3 population was observed when marrow cells were cultured with IL-2 alone or with stimulating feeder cells. These results, obtained in a series of 14 patients with precursor B-ALL, were significantly different when compared with expansions from normal marrow cells. In one patient, the clones established from the expanded population displayed different patterns of cytotoxicity against tumoral targets of the B cell lineage. Some clones expressing the TCR V delta 1 segment showed cytotoxic activity against a cell line derived from a pre-B ALL without activity against a LAK-sensitive B cell line. Using PCR amplification, one such clone was detected at high frequency, in the primary expansion of ALL marrow cells. These results suggest a prior activation in vivo of some gamma delta T cells by leukemic cells and provide some evidence on the role of these subsets in the immune response to leukemia.
Duval
M
M
Service d'Hémato-Immunologie, Hôpital Robert Debré, Paris.
Yotnda
P
P
Bensussan
A
A
Oudhiri
N
N
Guidal
C
C
Rohrlich
P
P
Boumsell
L
L
Grandchamp
B
B
Vilmer
E
E
D000293:Adolescent; D001483:Base Sequence; D001853:Bone Marrow / Q000187:drug effects / Q000473:pathology; D002478:Cells, Cultured; D002648:Child; D002675:Child, Preschool; D003001:Cloning, Molecular; D004273:DNA, Neoplasm / Q000032:analysis; D006801:Humans; D016219:Immunotherapy, Adoptive; D007223:Infant; D007376:Interleukin-2 / Q000494:pharmacology; D008213:Lymphocyte Activation / Q000187:drug effects; D008969:Molecular Sequence Data; D016133:Polymerase Chain Reaction; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000276:immunology* / Q000628:therapy*; D016692:Receptors, Antigen, T-Cell, gamma-delta / Q000276:immunology* / Q000502:physiology; D016176:T-Lymphocyte Subsets; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology* / Q000648:ultrastructure*; D014407:Tumor Cells, Cultured
D004273:DNA, Neoplasm; D007376:Interleukin-2; D016692:Receptors, Antigen, T-Cell, gamma-delta